Drug Trial Radar · NCT06130722
First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study
Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Dec 30, 2023
Primary completion
Feb 15, 2025
Study completion Sep 19, 2025
Sponsor
- Lead sponsor
- Suzhou Forlong Biotechnology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
First-in-Human, Phase I, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of FL115 in patients with advanced solid tumors who have progressed or are intolerant to current standard-of-care therapies, including immune check-point inhibitors administered in single-agent or combination use.
Conditions
- Locally Advanced/Metastatic Solid Tumors
Interventions
FL115Drug
FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of FL115 in approximately 26 patients with unresectable locally advanced or metastatic solid tumorsTime frame: From screening to 30 days after last dose.
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
HOAG Memorial Hospital Presbyterian
Newport Beach, California
Moores Cancer Center at UCSD Health
San Diego, California
Gabriel Cancer Center
Canton, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.